Sugarloaf Wealth Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-159
| Closed | -$6.14K | – | 689 |
|
|
2024
Q2 | $6.14K | Buy |
159
+1
| +0.6% | +$39 | ﹤0.01% | 518 |
|
|
2024
Q1 | $6.77K | Buy |
158
+1
| +0.6% | +$43 | ﹤0.01% | 515 |
|
|
2023
Q4 | $5.8K | Sell |
157
-230
| -59% | -$8.5K | ﹤0.01% | 535 |
|
|
2023
Q3 | $14K | Buy |
387
+1
| +0.3% | +$36 | ﹤0.01% | 428 |
|
|
2023
Q2 | $13.7K | Sell |
386
-32
| -8% | -$1.14K | ﹤0.01% | 439 |
|
|
2023
Q1 | $14.9K | Buy |
418
+35
| +9% | +$1.25K | ﹤0.01% | 430 |
|
|
2022
Q4 | $13.5K | Buy |
383
+2
| +0.5% | +$70 | ﹤0.01% | 457 |
|
|
2022
Q3 | $12K | Sell |
381
-1
| -0.3% | -$31 | ﹤0.01% | 493 |
|
|
2022
Q2 | $21K | Buy |
382
+3
| +0.8% | +$165 | 0.01% | 396 |
|
|
2022
Q1 | $21K | Buy |
379
+1
| +0.3% | +$55 | 0.01% | 391 |
|
|
2021
Q4 | $21K | Buy |
378
+2
| +0.5% | +$111 | 0.01% | 417 |
|
|
2021
Q3 | $18K | Buy |
376
+2
| +0.5% | +$96 | ﹤0.01% | 440 |
|
|
2021
Q2 | $19K | Buy |
374
+3
| +0.8% | +$152 | 0.01% | 416 |
|
|
2021
Q1 | $17 | Buy |
371
+1
| +0.3% | – | 0.01% | 435 |
|
|
2020
Q4 | $17K | Buy |
370
+2
| +0.5% | +$92 | 0.01% | 406 |
|
|
2020
Q3 | $17K | Buy |
368
+2
| +0.5% | +$92 | 0.01% | 381 |
|
|
2020
Q2 | $19K | Buy |
366
+1
| +0.3% | +$52 | 0.01% | 356 |
|
|
2020
Q1 | $17K | Buy |
365
+2
| +0.6% | +$93 | 0.01% | 357 |
|
|
2019
Q4 | $21K | Buy |
+363
| New | +$21K | 0.01% | 360 |
|